Eikon Therapeutics has raised $1.16 billion in total funding, including a $518 million Series B round on January 6, 2022, led by T. Rowe Price, CPP Investments, and EcoR1 Capital, valuing it at $3.1 billion. Founded in 2019 and based in Hayward, California, Eikon develops protein-tracking and measurement platforms for drug discovery using super-resolution microscopy and AI-driven analytics. With 11–50 employees, Eikon is transforming how researchers visualize protein behavior, aiming to accelerate breakthroughs in oncology, immunology, and therapeutic development.